The immunobiology of human papillomavirus associated oncogenesis

Peter L. Stern, Mark Einstein

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The lifecycle of oncogenic HPV begins with entry into the basal cells of a target anogenital epithelium. Thereafter, virus production is entirely within and dependent on the differentiation of the epithelium which provides for the necessary coordinated cellular and viral gene expression leading to accumulation of infectious virions in the terminally differentiated cells. Natural immune control of such HPV infection derives initially from activation of innate immune mechanisms and these stimulate adaptive immunity such as specific cytotoxic T cells recognizing viral proteins E2, E6 and E7 that can clear the virally infected cells. About 50% of women who clear their infections also make neutralising antibodies but the levels are not necessarily protective against a subsequent infection by the same HPV type and are never therapeutic. Oncogenic HPVs have several immune evasion strategies which together with a lifecycle involving little or no damage in the epithelial located infection can allow for persistent infection, which is the major risk factor for development of intraepithelial neoplasia. Oncogenic HPV infection is necessary but insufficient for development of a cervical cancer and additional genetic changes are acquired over time through selection including those that allow for escape from immune surveillance. This review describes the current understanding natural immune control and identifies the unique hurdles in prophylactic and therapeutic vaccine design for HPV compared to other common viral pathogens.

Original languageEnglish (US)
Title of host publicationHPV and Cervical Cancer
Subtitle of host publicationAchievements in Prevention and Future Prospects
PublisherSpringer New York
Pages45-61
Number of pages17
Volume9781461419884
ISBN (Electronic)9781461419884
ISBN (Print)1461419875, 9781461419877
DOIs
StatePublished - Sep 1 2012

Fingerprint

Carcinogenesis
Infection
Epithelium
Immune Evasion
Papillomavirus Vaccines
Viral Genes
Adaptive Immunity
Viral Proteins
Neutralizing Antibodies
Uterine Cervical Neoplasms
Virion
Viruses
T-Lymphocytes
Gene Expression
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Stern, P. L., & Einstein, M. (2012). The immunobiology of human papillomavirus associated oncogenesis. In HPV and Cervical Cancer: Achievements in Prevention and Future Prospects (Vol. 9781461419884, pp. 45-61). Springer New York. https://doi.org/10.1007/978-1-4614-1988-4_3
Stern, Peter L. ; Einstein, Mark. / The immunobiology of human papillomavirus associated oncogenesis. HPV and Cervical Cancer: Achievements in Prevention and Future Prospects. Vol. 9781461419884 Springer New York, 2012. pp. 45-61
@inbook{4d85118c6df04ef0835fccf44e9991ad,
title = "The immunobiology of human papillomavirus associated oncogenesis",
abstract = "The lifecycle of oncogenic HPV begins with entry into the basal cells of a target anogenital epithelium. Thereafter, virus production is entirely within and dependent on the differentiation of the epithelium which provides for the necessary coordinated cellular and viral gene expression leading to accumulation of infectious virions in the terminally differentiated cells. Natural immune control of such HPV infection derives initially from activation of innate immune mechanisms and these stimulate adaptive immunity such as specific cytotoxic T cells recognizing viral proteins E2, E6 and E7 that can clear the virally infected cells. About 50{\%} of women who clear their infections also make neutralising antibodies but the levels are not necessarily protective against a subsequent infection by the same HPV type and are never therapeutic. Oncogenic HPVs have several immune evasion strategies which together with a lifecycle involving little or no damage in the epithelial located infection can allow for persistent infection, which is the major risk factor for development of intraepithelial neoplasia. Oncogenic HPV infection is necessary but insufficient for development of a cervical cancer and additional genetic changes are acquired over time through selection including those that allow for escape from immune surveillance. This review describes the current understanding natural immune control and identifies the unique hurdles in prophylactic and therapeutic vaccine design for HPV compared to other common viral pathogens.",
author = "Stern, {Peter L.} and Mark Einstein",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/978-1-4614-1988-4_3",
language = "English (US)",
isbn = "1461419875",
volume = "9781461419884",
pages = "45--61",
booktitle = "HPV and Cervical Cancer",
publisher = "Springer New York",
address = "United States",

}

Stern, PL & Einstein, M 2012, The immunobiology of human papillomavirus associated oncogenesis. in HPV and Cervical Cancer: Achievements in Prevention and Future Prospects. vol. 9781461419884, Springer New York, pp. 45-61. https://doi.org/10.1007/978-1-4614-1988-4_3

The immunobiology of human papillomavirus associated oncogenesis. / Stern, Peter L.; Einstein, Mark.

HPV and Cervical Cancer: Achievements in Prevention and Future Prospects. Vol. 9781461419884 Springer New York, 2012. p. 45-61.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - The immunobiology of human papillomavirus associated oncogenesis

AU - Stern, Peter L.

AU - Einstein, Mark

PY - 2012/9/1

Y1 - 2012/9/1

N2 - The lifecycle of oncogenic HPV begins with entry into the basal cells of a target anogenital epithelium. Thereafter, virus production is entirely within and dependent on the differentiation of the epithelium which provides for the necessary coordinated cellular and viral gene expression leading to accumulation of infectious virions in the terminally differentiated cells. Natural immune control of such HPV infection derives initially from activation of innate immune mechanisms and these stimulate adaptive immunity such as specific cytotoxic T cells recognizing viral proteins E2, E6 and E7 that can clear the virally infected cells. About 50% of women who clear their infections also make neutralising antibodies but the levels are not necessarily protective against a subsequent infection by the same HPV type and are never therapeutic. Oncogenic HPVs have several immune evasion strategies which together with a lifecycle involving little or no damage in the epithelial located infection can allow for persistent infection, which is the major risk factor for development of intraepithelial neoplasia. Oncogenic HPV infection is necessary but insufficient for development of a cervical cancer and additional genetic changes are acquired over time through selection including those that allow for escape from immune surveillance. This review describes the current understanding natural immune control and identifies the unique hurdles in prophylactic and therapeutic vaccine design for HPV compared to other common viral pathogens.

AB - The lifecycle of oncogenic HPV begins with entry into the basal cells of a target anogenital epithelium. Thereafter, virus production is entirely within and dependent on the differentiation of the epithelium which provides for the necessary coordinated cellular and viral gene expression leading to accumulation of infectious virions in the terminally differentiated cells. Natural immune control of such HPV infection derives initially from activation of innate immune mechanisms and these stimulate adaptive immunity such as specific cytotoxic T cells recognizing viral proteins E2, E6 and E7 that can clear the virally infected cells. About 50% of women who clear their infections also make neutralising antibodies but the levels are not necessarily protective against a subsequent infection by the same HPV type and are never therapeutic. Oncogenic HPVs have several immune evasion strategies which together with a lifecycle involving little or no damage in the epithelial located infection can allow for persistent infection, which is the major risk factor for development of intraepithelial neoplasia. Oncogenic HPV infection is necessary but insufficient for development of a cervical cancer and additional genetic changes are acquired over time through selection including those that allow for escape from immune surveillance. This review describes the current understanding natural immune control and identifies the unique hurdles in prophylactic and therapeutic vaccine design for HPV compared to other common viral pathogens.

UR - http://www.scopus.com/inward/record.url?scp=84949178442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949178442&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-1988-4_3

DO - 10.1007/978-1-4614-1988-4_3

M3 - Chapter

SN - 1461419875

SN - 9781461419877

VL - 9781461419884

SP - 45

EP - 61

BT - HPV and Cervical Cancer

PB - Springer New York

ER -

Stern PL, Einstein M. The immunobiology of human papillomavirus associated oncogenesis. In HPV and Cervical Cancer: Achievements in Prevention and Future Prospects. Vol. 9781461419884. Springer New York. 2012. p. 45-61 https://doi.org/10.1007/978-1-4614-1988-4_3